Vivos Therapeutics earnings were -$25.5M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest VVOS earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$5.5M, down 28.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VVOS reported annual earnings of -$21.2M, with 90.1% growth. The next VVOS earnings date is Nov 18, 2026.
What were Vivos Therapeutics's earnings last quarter?
On VVOS's earnings call on Aug 18, 2026, Vivos Therapeutics (NASDAQ: VVOS) reported Q2 2026 earnings per share (EPS) of -$0.31, up 43.64% year over year. Total VVOS earnings for the quarter were -$5.48 million. In the same quarter last year, Vivos Therapeutics's earnings per share (EPS) was -$0.55.
The next VVOS earnings call is Nov 18, 2026. Add VVOS to your watchlist to be reminded of Vivos Therapeutics's next earnings date.
Is Vivos Therapeutics profitable or losing money?
As of the last Vivos Therapeutics earnings report, Vivos Therapeutics is currently losing money. Vivos Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$25.46 million, a 77.77% increase year over year.
What was VVOS's earnings growth in the past year?
As of Vivos Therapeutics's earnings date in Aug 18, 2026, Vivos Therapeutics's earnings has grown year over year. VVOS earnings in the past year totalled -$25.46 million.
What are Vivos Therapeutics's earnings expectations?
The current EPS estimate for Vivos Therapeutics's earnings report in Nov 18, 2026 is -$0.28.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.